retatrutide phase 2 trial results weight loss just delivered the first top-line 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Phase 2 trial results demonstrate

It does so through a variety of mechanisms, such as enhancing insulin sensitivity and promoting healthy glucose metabolism

& Atalar, A

We urge you to join usbecome a member of PAS to amplify your voice, support by donating, and taking part in our vital research into areas like SC administration and individualised frequency, and like and follow us on social media to ensure this consistent message reaches every corner of the healthcare system

For example, previous studies have noted a decrease in preference for starchy foods (Wharton et al., 2022), dairy (Friedrichsen et al., 2021, Wharton et al., 2022), sweets (Friedrichsen et al., 2021, Kadouh et al., 2020, Gibbons et al., 2021), savory foods (Friedrichsen et al., 2021, Kadouh et al., 2020), and high-fat foods (Blundell et al., 2017, Gibbons et al., 2021, Kadouh et al., 2020)

For tesamorelin, known adverse effects (based on US and Canadian prescribing information, as no UK Summary of Product Characteristics exists) include: Fluid retention (oedema, joint pain, carpal tunnel syndrome) Elevated blood glucose and reduced insulin sensitivity due to GH elevation Injection site reactions Raised IGF-1 levels active malignancy is a key contraindication